Monocyte/HDL ratio in sarcoidosis patients without treatment

Aim: This study examined the effects of monocyte/high-density lipoprotein cholesterol (HDL-C) ratio (MHR) and other inflammatorymarkers in patients with sarcoidosis not receiving treatment. To our knowledge, this is the first study on the relationship betweensarcoidosis and MHR.Material and Methods: This study included 53 patients with sarcoidosis who were followed at a single, outpatient tertiary-carecentre. Data on patient demographics (age and gender), disease characteristics (duration of disease, radiographic stage, treatments);pulmonary function tests (% predicted values for forced vital capacity [FVC], forced expiratory volume at 1 second [FEV1], diffusingcapacity of the lungs for carbon monoxide [DLCO], alveolar volume [VA], forced expiratory flow [25–75% and at 50%; FEF] [FEF25-75]),blood biochemistry and hemogram findings were retrieved from hospital records.Results: Mean ± SD patient age was 51.13 ±1 1.94 years. Of the 53 patients, 42 were female and 11 were male. When compared withMHR ratio and pulmonary function test parameters, there was a negative correlation with FEV1% (P = 0.043, r = −0.279) and DLCO% (P= 0.009, r = –0.360). There was no significant correlation between FVC, FEV25-75 or VA. No significant correlation was found betweenblood calcium, urinary calcium, SACE (serum angiotensin converting enzyme) values and MHO ratio.Conclusions: Large-scale prospective studies are needed to determine if the use of MHR as an indicator of inflammation andactivation would be helpful in the diagnosis and monitoring of patients with sarcoidosis.

PDF

___

1. Rybicki BA, Major M, Popovich J, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234-41.
2. Rybicki BA, Maliarik MJ, Major M, et al. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect 1998;13:166-73.
3. Gunaydin FE, Turan D, Yildirim BZ, et al. A Case of Sarcoidosis with Diffuse Cavitary Lesion in the Lung. İstanbul Med J 2019;20:356-9.
4. Musellim B, Kumbasar OO, Ongen G, et al. Epidemiological features of Turkish patients with sarcoidosis. Respir Med 2009;103:907-12.
5. Caruana LB, Redwine GD, Rohde RE, et al. A prospective study of patients diagnosed with sarcoidosis: Factors -environmental exposure, health assessment, and genetic outlooks. Sarcoidosis VDLD 2019;36:228-42.
6. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65.
7. Yildiz Gulhan P, Gulec Balbay E, Erçelik M, et al. Is sarcoidosis related to metabolic syndrome and insulin resistance? Aging Male 2020;23:53-8.
8. Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 1999;14:735-7.
9. Kutlu O. Effect of isotretinoin treatment on the inflammatory markers in patients with acne vulgaris: can monocyte/HDL be a new indicator for inflammatory activity of isotretinoin treatment?. Cutan Ocul Toxicol 2020;39:67-70.
10. Hristov M, Heine GH. Monocyte subsets in atherosclerosis. Hamostaseologie 2015;35:105-12.
11. Akboga MK, Balci KG, Maden O, et al. Usefulness of monocyte to HDL-cholesterol ratio to predict high SYNTAX score in patients with stable coronary artery disease. Biomark Med 2016;10:375-83.
12. Zhang Y, Li S, Guo Y, et al. Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Ann Med 2016;48:305-12.
13. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), adopted by the ATS Board of Directors and by the ERS Executive Committee. Am J Respir Crit Care Med 1999;160:736-55.
14. Kieszko R, Krawczyk P, Jankowska O, et al. The clinical significance of interleukin 18 assessment in sarcoidosis patients. Respiratory Med 2007;101:722- 8.
15. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224-34.
16. Richards CD. The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm 2013:512103.
17. Guber A, Jawad AQ, Salomon P et al. Oncostatin M in bronchoalveolar lavage correlates with the severity of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30:194-200.
18. Bilyk C, Holt PG. Cytokine modulation of the immunosuppressive phenotype of pulmonary alveolar macrophage population. Immunology 1995;86:231-7.
19. Ziora D, Kałuska K, Kozielski J. An increase in exhaled nitric oxide is not associated with activity in pulmonary sarcoidosis. European Respiratory J 2004;24:609-14.
20. Postlethwaite AE, Jackson BK, Beachey EH, et al. Formation of multi-nucleated giant cells from human monocyte precursors. Mediation by a soluble protein from antigen- and mitogen-stimulated lymphocytes. J Exp Med 1982;155:168-78.
21. Möst J, Spötl L, Mayr D, et al. Formation of multinucleated giant cells in vitro is dependent on the stage of monocyte to macrophage maturation. Blood 1997;89:662-71.
22. Mizuno K, Okamoto H, Horio T. Heightened ability of monocytes from sarcoidosis patients to form multi-nucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells. Clinical & Experimental Immunology 2001;126:151-6.